Acne vulgaris can be associated with hyperpigmentation, particularly in individuals with skin of color. This acne-induced macular hyperpigmentation (AMH), also called postinflammatory hyperpigmentation, is often long lasting and negatively impacts quality of life. Large-scale, randomized, controlled clinical trials with regard to the treatment of acne and AMH are lacking. For this reason, evidence-based treatment recommendations cannot be made. However, AMH is a common condition, and it is important for clinicians to have guidance on management strategies. The authors, a group of 10 board-certified dermatologists, conducted a modified Delphi consensus process to reach a consensus on first-line therapy for AMH and determine whether therapeutic choices change in different patient subgroups. We reached a consensus that most patients with acne and AMH should receive early and efficacious acne treatment with a topical retinoid and benzoyl peroxide. Therapies aimed at addressing AMH-including hydroquinone, azelaic acid, chemical peel, or antioxidants-may also be considered for enhancing the effect of the treatment regimen on acne and pigmentation. Chemical peels may be used as adjunctive or second-line therapy. This article details the results of the Delphi process, reviews relevant literature for providing recommendations for AMH, and discusses appropriate treatment options., Competing Interests: Conflicts of interest Dr Taylor has served as a consultant, advisory board member, speaker, and/or investigator for AbbVie, Allergan Aesthetics, Arcutis Biotherapeutics, Armis Scientific, Avita Medical, Beiersdorf, Bristol Myers Squibb, Cara Therapeutics, Concert Pharmaceuticals, Croma-Pharma GmbH, Dior, Eli Lilly, EPI Pharma, Evolus, Galderma Laboratories LP, GloGetter, Hugel America, Johnson & Johnson Consumer Products Company, L’Oreal USA, MedScape, Pfizer, Piction Health, Sanofi, Scientis, UCB, and Vichy Laboratories. Dr Elbuluk has served as a paid consultant and/or advisory board member or speaker for Allergan, Beiersdorf, La Roche Posay, VisualDx, Scientis, Galderma Laboratories LP, Zosano, Incyte, Estee Lauder, Scientis, and Avita and has received fees for being a Unilever partner. Dr Grimes has served as a consultant for Galderma Laboratories LP, UpToDate, and Proctor & Gamble; received grants from Incyte, VT Technologies, Pfizer, SUN, and Arcutis; and has lectured for Scientis (Cyspera). Dr Chien has served as a consultant and/or advisory board member for Galderma Laboratories LP and Under Armour; has served as an investigator for and received grants from Boots Walgreen Alliance and Amorepacific, Inc; and has been a contributing author receiving honoraria for UpToDate, Inc. Dr Hamzavi has served as a consultant and/or advisory board member for Galderma Laboratories LP, AbbVie, Incyte, Pfizer, UCB, Boehringer Ingelheim, and Clarify Medical; has served as an investigator for Pfizer Inc, Bayer, Lenicura, Incyte, Estee Lauder, Ferndale Laboratories, Inc, Galderma Laboratories LP, L’Oreal, Unigen, Arcutis, and Avita; and is cochair of the Global Vitiligo Foundation. Dr Alexis has served as a consultant and/or advisory board member for Leo, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Beiersdorf, Valeant, L’Oreal, BMS, Bausch health, UCB, Vyne, Arcutis, Janssen, Allergan, Almirall, AbbVie, Sol-Gel, Amgen, VisualDx, Eli Lilly, Swiss American, and Cutera; has served as a speaker for Regeneron, SANOFI-Genzyme, Pfizer, and BMS; and has received royalties from Springer Verlag, Wiley Blackwell, and Wolters Kluwer. Dr Weiss has served as a speaker for AbbVie, Almirall, Galderma Laboratories LP, Ortho Dermatologics, Regeneron, and Sanofi; consultant and/or advisory board member for Cassiopia, Cutera Inc, Dr Reddy, EPI Health, Foamix, Galderma Laboratories LP, Incyte, Leo Pharma, Novartis, Ortho Dermatologics, and UCB; and investigator for AbbVie, Aclaris, Bausch Health, Celgene/Amgen, Cutera, Endo, Foamix, Galderma Laboratories LP, Leo Pharma, Moberg, and Novartis. Dr Kang has served as a consultant and investigator for Almirall and Galderma Laboratories LP. Dr Desai serves as a consultant and/or investigator for a variety of different organizations, including Galderma, Pfizer, Incyte, Eli Lilly, L’Oreal, and others. He also serves in numerous leadership capacities within dermatology. Dr Gonzalez has no conflicts of interest to declare., (Copyright © 2023. Published by Elsevier Inc.)